Shamir Mehta of McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among patients with acute coronary syndromes. For a comment on Shamir Mehta’s presentation at the ESC meeting, Audio Medica questioned Freek Verheugt of Nijmegen.
Shamir Mehta:
Freek Verheugt:
Reporting from:
European Society of Cardiology Congress September 3-7, 2005, Stockholm
Scientific Editors:
Michael Petch, Papworth Hospital, Cambridge
Man Fai Shiu, Walsgrave Hospital, Coventry
James
Gregg Stone, Columbia University Medical Center, New York
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
A superiority for
Post a comment